A5101999552- Inflammatory Bowel Disease
- Microscopic Colitis
- Diverticular Disease and Complications
- Pharmaceutical studies and practices
- Anorectal Disease Treatments and Outcomes
- Biosimilars and Bioanalytical Methods
- Diagnosis and treatment of tuberculosis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Colorectal Cancer Treatments and Studies
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Screening and Detection
- Cytokine Signaling Pathways and Interactions
- Hidradenitis Suppurativa and Treatments
- Pharmacological Effects of Natural Compounds
- Clostridium difficile and Clostridium perfringens research
- Stoma care and complications
- Gut microbiota and health
- Gastrointestinal Tumor Research and Treatment
- Biliary and Gastrointestinal Fistulas
- Appendicitis Diagnosis and Management
- Mycobacterium research and diagnosis
- Pelvic floor disorders treatments
- Biomarkers in Disease Mechanisms
- Liver Diseases and Immunity
University of Szeged
2023-2025
University of Debrecen
2025
Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety adipose-derived mesenchymal stem cell treatment are contradicting, real-world evidence is lacking.
Abstract Background Data are scarce on the deep remission of tofacitinib (TOFA) in moderate-to severe ulcerative colitis (UC), however, it can fundamentally change disease course and behaviour. Methods This was a prospective cohort study, assessing short-term effectiveness TOFA UC patients. Baseline day induction TOFA. Clinical, biochemical, endoscopic histological activities were assessed at baseline week 8 12, we collected one-year treatment persistence. Primary outcome 12 (HR), defined as...
Abstract Background Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) Crohn’s disease (CD) are limited. Methods We conducted a multicenter, retrospective study to assess clinical, biochemical, endoscopic outcomes JAKis bio-experienced UC CD patients. Corticosteroid-free clinical remission (CSFCR) was defined as (CR; CDAI<150 CD, partial Mayo score ≤2 with rectal bleeding subscore 0 UC) not receiving local systemic steroids...
Abstract Background Perianal fistulas of Crohn’s disease (CD) create a significant burden on patient lives. However, the efficacy and safety adipose-derived mesenchymal stem cell treatment are contradicting, real-world evidence is lacking. We aimed to examine usability darvadstrocel therapy in managing perianal CD. Methods In this retrospective multicenter study CD patients with were enrolled followed. The primary outcome was clinical remission (all treated have closed) at weeks 26 52, while...
Abstract Background Data suggest that patients’ knowledge about their chronic disease is associated with treatment adherence, and education may help improve outcomes. The effectiveness of educational activities depends on the source information. Our study aimed to compare targeted in written podcast formats for patients inflammatory bowel (IBD). Methods In this nationwide randomized controlled trial, IBD were enrolled between December 2023 May 2024. At baseline, completed an online...
Abstract Background Crohn’s disease (CD) complicated with intra-abdominal abscess often requires surgical intervention. Image guided percutaneous drainage (PD) can help to avoid interventions, however there is limited evidence on the optimal management after PD. Our study aimed analyze long-term outcomes of CD Methods In this multicenter, multinational retrospective trial penetrating patients simplex were enrolled and followed. Baseline was defined as day first detection abdominal abscess,...
Abstract Background Limited comparative data is available on the real-world effectiveness and safety of tofacitinib (TOFA) upadacitinib (UPA) in ulcerative colitis (UC). Methods We conducted an international, multicenter, real-life retrospective cohort study to assess compare short-term TOFA UPA bio-experienced, moderate-to-severe UC. The primary outcome was week 12 corticosteroid-free remission (CSFR) defined as clinical (CR; partial Mayo score [pMayo]<2 with a rectal bleeding...
Abstract Background Inflammatory Bowel Diseases (IBD) require lifelong treatment and patient monitoring. Current predictors of relapse therapeutic success have limitations, mostly invasive, time-consuming, expensive. The faecal biomarker can help in disease activity response monitoring by simple non-invasive way. Faecal Calprotectin (FC) is the gold-standard, but it has many disadvantages. We previously described that correlation between Plasminogen activator inhibitor type 1 (PAI-1) (FP)...
Abstract Background High-quality endoscopy in IBD is associated with better clinical outcomes, while quality measurement supports effective control. The European Society of Gastrointestinal Endoscopy recommends using nine performance measures, depending on the indication for endoscopic examination IBD. Our study aimed to compare colonoscopy between tertiary and secondary referral centers patients, based reports. Methods In this cross-sectional study, reports patients were analyzed. At our...
Abstract Background There is a constant search for non-invasive evaluation methods the identification of fibrosis in patients treated Crohn’s disease, since this condition can severely impact patients’ quality life long run. While PET/CT mostly used oncological evaluation, it was previously proved that be useful inflammation associated with disease activity, segmental FDG uptake proportional immune cell infiltration bowel. However, it’s role detection needs further evaluation. Our aim to...
Abstract Background Perianal involvement affects approximately 20-30% of Crohn’s Disease patients, significantly impairing their quality life. Anti-tumor necrosis factor-α inhibitors (anti-TNFs) are still the established biological treatment for perianal Crohn's disease (pCD). However, relapse and non-response frequent evidence regarding effectiveness 2nd- 3rd-line biologics is limited. This study aims to compare efficacy in patients with pCD who have previously failed 1st-line anti-TNF...
Abstract Background Bowel urgency is one of the most bothersome symptoms ulcerative colitis (UC). The Urgency Numerical Rating Scale (U-NRS) measures degree faecal experienced over past 24 hours by patients with UC on a scale 0-10. We assumed that has large variance, as evaluate their own differently. urge may be different quality for two same score. score U-NRS influenced individual’s specific perception (degree pain, speed urge). objective our study was to investigate possible components...
Abstract Background Biosimilars are highly similar to the already approved reference biological medication, and potentially more accessible widespread due better cost-effectiveness. However, both effectiveness immunogenicity may differ structure characteristics. In 2020, non-medical switch was obligated from originator infliximab (IFX) biosimilar GP1111 amongst inflammatory bowel disease (IBD, Crohns’s [CD], ulcerative colitis [UC]) patients in Hungary. As data regarding lacking IBD, thus we...
A rectovaginalis fistula a penetráló Crohn-betegség ritka szövődménye, jelenléte esetén gyógyszeres kezelés és sebészeti beavatkozás együttes alkalmazása javasolt. Habár perianalis sipollyal szövődött TNFα-blokkolók hatékonyak lehetnek, kisebb hatékonyság mutatkozik, feltehetően anatómiai okok, valamint gyulladás talaján megváltozott szövetekbe történő csökkent penetrációs készség miatt. Az újabb biologikumok kis molekulájú szerek hatékonyságáról biztonságosságáról Crohn-betegségben kevés...
Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, endoscopic outcomes JAKis bio-experienced UC CD. Results: A total 246 patients (mean age: 40.5 ± 14.5 years; 131 115 CD) were included with median follow-up 7.5 months. Among CD receiving upadacitinib (n = 115), 76.2% achieved clinical...
Abstract Background Usability of subcutaneous vedolizumab (SC VDZ) in inflammatory bowel diseases (IBD, ulcerative colitis [UC], Crohn’s disease [CD]) have proved via clinical trials, while real-world data collection is ongoing. Experiences Central-European population and assessment patient’s perspectives are lacking. Our study aimed to evaluate the efficacy, safety preferences SC VDZ maintenance treatment after switching from intravenous (IV) formulation a Hungarian IBD cohort. Methods In...
Abstract Background First generation of biologicals (infliximab (IFX) and adalimumab (ADA)) has revolutionised the treatment patients with Crohn’s disease (CD) ulcerative colitis (UC), however, primary resistance or loss efficacy are serious clinical challenges. Although there is currently insufficient evidence to recommend for against use therapeutic drug monitoring improve outcomes, determination IFX ADA levels point-of-care tests (POCT) fast, simple can be a helpful tool guide therapy....
Abstract Background While randomized controlled trials have shown ustekinumab (UST) as an effective therapeutic option for Crohn’s disease (CD), there is a lack of long-term observational data in real-world CD patient settings. This prospective study seeks to evaluate the clinical effectiveness, sustainability, and safety UST nationwide multicentre cohort patients over three years. The aim bridge gap our understanding UST's implications management. Methods undergoing treatment were...
Abstract Background In contrast to the increasingly rigorous endpoints of clinical trials ulcerative colitis (UC), Mayo endoscopic score (MES) ≤ 1 is mostly set as target during follow-up, but long-term outcomes may differ according different level healing. Therefore, our study aimed compare UC patients in remission with MES and UCEIS scores real-life condition. Methods (defined by pMayo<2 no rectal bleeding) who underwent colonoscopy between 2016-2020 were consecutively enrolled this...
Abstract Background The development of anti-TNFs has brought major advances in the treatment ulcerative colitis (UC). Yet, a significant proportion patients do not respond favorably to first-line anti-TNF therapy, which may require use second-, third-, or fourth-line biologics small molecules. Treatment selection and sequencing, however, remains unmet need. Methods We conducted multicenter, retrospective study including with moderate-to-severe UC who failed anti-TNFs, received sequential...
Aims Colonoscopy plays a crucial role in management of ulcerative colitis (UC) that helps to assess mucosal healing. Different scoring systems are available severity, however most them do not correlate with disease extent. Our study aimed the predictive value and accuracy PanMayo score compared MES, UCEIS Dublin mid- long-term outcomes.
Lay Summary In this case of a young female, ulcerations around the ileostoma appeared after colectomy and were thought to be due surgical site infection. Given inadequate treatment, an extensive defect abdominal wall developed. Peristomal pyoderma gangrenosum was diagnosed, for which ustekinumab given successfully.